Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Enrolling by invitation Not applicable Interventional

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

NCT00102544
View directory record Official record
Conditions
Adenocarcinoma, Prostate Neoplasms, Prostate Cancer, Renal Cell Carcinoma, Von Hippel Lindau Disease
Interventions
EM Tracking
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 120 Years
Enrollment
3,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Completed No phase listed Observational Results available

Renal Retention of Microbubbles

NCT01647464
View directory record Official record
Conditions
- Study Focus: Renal Retention of Lipid Microbubbles
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Not applicable Interventional

COMEX Study for Dialysis Patients

NCT03055299
View directory record Official record
Conditions
ESRD
Interventions
COMEX intervention
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Not applicable Interventional Results available

Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study

NCT00921687
View directory record Official record
Conditions
Chronic Renal Insufficiency
Interventions
Education only, Multifactorial intervention
Behavioral
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 27, 2026, 3:22 AM EDT
Recruiting Phase 2 Interventional

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

NCT06083922
View directory record Official record
Conditions
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
Interventions
Cyclophosphamide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Recruiting Phase 1 Interventional

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

NCT06056102
View directory record Official record
Conditions
Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
Interventions
Cyclophosphamide, CART-BCMA, huCART19
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

NCT04909853
View directory record Official record
Conditions
Renal Impairment
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 27, 2026, 3:22 AM EDT
Recruiting Early Phase 1 Interventional

Fecal Microbiota Transplantation in Kidney Stone Patients

NCT05516472
View directory record Official record
Conditions
Kidney Stones
Interventions
Microbial Transplant Therapy, Placebo
Drug
Lead sponsor
Joshua Stern
Other
Eligibility
18 Years to 69 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Park City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Alkali Therapy in Chronic Kidney Disease

NCT01452412
View directory record Official record
Conditions
Chronic Kidney Disease, Metabolic Acidosis
Interventions
Sodium bicarbonate, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
19 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
The Bronx, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Phase 4 Interventional Results available

Narcotic-Free Percutaneous Nephrolithotomy

NCT05924165
View directory record Official record
Conditions
Nephrolithiasis
Interventions
5mg Oxycodone, Q6 PRN, 10mg Ketorolac, Q6 PRN
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 27, 2026, 3:22 AM EDT
Terminated Phase 3 Interventional

Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

NCT00004465
View directory record Official record
Conditions
Hemolytic Uremic Syndrome
Interventions
SYNSORB Pk, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
26
States / cities
Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 27, 2026, 3:22 AM EDT
Not listed Not applicable Interventional

Gut Microbiome and p-Inulin in CKD - TarGut CKD Study

NCT03348592
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Oligofructose-enriched inulin (p-inulin), No treatment
Dietary Supplement · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 27, 2026, 3:22 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

NCT03816332
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma
Interventions
Ipilimumab, Nivolumab, Prednisone, Tacrolimus
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Not listed Phase 2 Interventional

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

NCT00717587
View directory record Official record
Conditions
Kidney Cancer
Interventions
motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

NCT00458536
View directory record Official record
Conditions
Renal Cancer
Interventions
Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Biological · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant

NCT00928811
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
basiliximab
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Not applicable Interventional Results available

An Effectiveness-Implementation Trial of SPIRIT in ESRD

NCT03138564
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
SPIRIT, Comparison Condition
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
39
States / cities
Atlanta, Georgia • Decatur, Georgia • North Decatur, Georgia + 29 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Azimilide Dihydrochloride on Renal Function

NCT00318838
View directory record Official record
Conditions
Healthy
Interventions
Azimilide dihydrochloride, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 27, 2026, 3:22 AM EDT
Not yet recruiting Phase 3 Interventional

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

NCT07083765
View directory record Official record
Conditions
Hypertension, Hypertension,Essential
Interventions
Dehydrated Alcohol Injection, USP, Sham procedure
Drug · Procedure
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

NCT01158534
View directory record Official record
Conditions
Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
celecoxib, recombinant interferon alfa-2b, polymerase chain reaction, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, immunologic technique, immunohistochemistry staining method, flow cytometry
Drug · Biological · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 27, 2026, 3:22 AM EDT
Recruiting Phase 3 Interventional

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

NCT06407232
View directory record Official record
Conditions
Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant
Interventions
Letermovir
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

NCT03824587
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Phosphate Binder Agents
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 27, 2026, 3:22 AM EDT
Completed Phase 2 Interventional

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

NCT04075916
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Epclusa
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Gainesville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 27, 2026, 3:22 AM EDT
Terminated Not applicable Interventional

Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

NCT00579592
View directory record Official record
Conditions
Acute Rejection, Renal Transplantation
Interventions
Campath-1H, rituximab, myfortic
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 27, 2026, 3:22 AM EDT